Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU generics group head Greg Perry departing to lead UNITAID's Medicines Patent Pool

This article was originally published in SRA

Executive Summary

Greg Perry, the director general of the European Generic medicines Association, will be leaving the organisation by the end of this year to head UNITAID's Medicines Patent Pool1,2. The EGA's deputy director general Beata Stepniewska will take interim charge of the association's day to day affairs after Mr Perry's departure.

You may also be interested in...



EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

EMA Set To Discuss Safety Of Ranitidine Drugs Soon

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

EU Pharma Urges Rethink On Knee-Jerk Trade Policies In Global COVID-19 Fight

EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.

UsernamePublicRestriction

Register

PS117048

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel